Display options
Cite
Campari C, Fedato C, Petrelli A, et al. HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs. Infect Agent Cancer. 2015;10:14doi: 10.1186/s13027-015-0009-x.
Campari, C., Fedato, C., Petrelli, A., Zorzi, M., Cogo, C., Caprioglio, A., Gallo, F., Giordano, L., Domenighini, S., Pasquale, L., Prandi, S., Zappa, M., Giorgi Rossi, P. (2015). HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs. Infectious agents and cancer, 1014. https://doi.org/10.1186/s13027-015-0009-x
Campari, Cinzia, et al. "HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs." Infectious agents and cancer vol. 10 (2015): 14. doi: https://doi.org/10.1186/s13027-015-0009-x
Campari C, Fedato C, Petrelli A, Zorzi M, Cogo C, Caprioglio A, Gallo F, Giordano L, Domenighini S, Pasquale L, Prandi S, Zappa M, Giorgi Rossi P. HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs. Infect Agent Cancer. 2015 May 07;10:14. doi: 10.1186/s13027-015-0009-x. eCollection 2015. PMID: 25969693; PMCID: PMC4427984.
Copy Download .nbib Format: NLM
Share it on

Infect Agent Cancer. 2015 May 07;10:14. doi: 10.1186/s13027-015-0009-x. eCollection 2015.

HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs.

Infectious agents and cancer

Cinzia Campari, Chiara Fedato, Alessio Petrelli, Manuel Zorzi, Carla Cogo, Adele Caprioglio, Federica Gallo, Livia Giordano, Serena Domenighini, Luigi Pasquale, Sonia Prandi, Marco Zappa, Paolo Giorgi Rossi,

Affiliations

  1. Staff Programmazione e Controllo, AUSL, Reggio Emilia, Italy ; IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.
  2. Coordinamento regionale screening oncologici, Regione Veneto, Venezia, Italy.
  3. INMP Istituto Nazionale per la promozione della salute delle popolazioni Migranti ed il contrasto delle malattie della Povertà, Rome, Italy.
  4. Registro Tumori del Veneto, Regione Veneto, Padova, Italy.
  5. Unità di Epidemiologia - CPO Piemonte, Torino, Italy.
  6. ASL Valle Camonica Sebino, Breno, BS Italy.
  7. Patologia IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.
  8. ISPO - Istituto per lo Studio e la Prevenzione Oncologica, Florence, Italy.
  9. IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy ; Servizio Interaziendale di Epidemiologia, AUSL, Reggio Emilia, Italy.

PMID: 25969693 PMCID: PMC4427984 DOI: 10.1186/s13027-015-0009-x

Abstract

UNLABELLED: ᅟ: Immigrants from low- and medium-income countries have a higher risk of cervical cancer due both to barriers in access to screening and to higher human papillomavirus (HPV) prevalence. In the near future many screening programmes in industrialised countries will replace Pap test with HPV as primary test. In order to plan future interventions, it is essential to understand how the HPV screening performs in immigrant women.

METHODS: We conducted a survey on the main performance indicators from some of the HPV DNA-based pilot programmes in Italy, comparing regular immigrant women, identified as women resident in Italy who were born abroad, with women who were born in Italy. All the programmes applied the same protocol, with HPV as stand-alone test starting for women of 25 or 35 to 64 years of age. Cytology triage is performed for positive women; those ASC-US or more severe are referred directly to colposcopy; negative women are referred to repeat HPV after one year.

RESULTS: Overall, 162,829 women were invited, of whom 22,814 were born abroad. Participation was higher for Italy-born than born abroad (52.2% vs. 43.6%), particularly for women over 45 years. HPV positivity rate was higher in immigrants: 7.8% vs. 6.1%, age-adjusted Relative Risk (age-adj RR) 1.18, 95% confidence interval (95% CI) 1.13-1.22. The proportion of women with positive cytology triage was similar in the two groups (42%). Cervical Intraepithelial Neoplasia (CIN) grade 2 or more severe detection rate was higher for born abroad (age-adj RR 1.65, 95% CI 1.45-1.89). The difference was stronger when considering only CIN3 or more severe (age-adj RR 2.29, 95% CI 1.90-2.75). Both HPV positivity and CIN2 or more severe detection rate had a different age curve in born abroad compared with Italy-born: in the former, the risk was almost flat, while in the latter it declined rapidly with age.

CONCLUSION: Compliance with HPV screening is lower for migrant women, who are affected by higher HPV positivity and CIN3 cancer detection rates.

References

  1. Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 2):e1-e33 - PubMed
  2. Epidemiol Prev. 2012 Jan;36(1 Suppl 1):1-104 - PubMed
  3. Pathologica. 2013 Jun;105(3):83-5 - PubMed
  4. Eur J Cancer. 2010 Sep;46(14):2647-59 - PubMed
  5. Eur J Cancer Prev. 2015 May;24(3):223-30 - PubMed
  6. Curr Pharm Des. 2013;19(8):1490-7 - PubMed
  7. Int J Cancer. 2012 Jul 15;131(2):497-504 - PubMed
  8. Eur J Cancer. 2002 Dec;38(18):2428-34 - PubMed
  9. J Med Screen. 2014 Mar;21(1):30-7 - PubMed
  10. Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):77-83 - PubMed
  11. J Immigr Minor Health. 2015 Jun;17 (3):670-8 - PubMed
  12. Lancet. 2014 Feb 8;383(9916):524-32 - PubMed
  13. J Immigr Minor Health. 2011 Feb;13(1):15-26 - PubMed
  14. Eur J Public Health. 2013 Oct;23(5):867-73 - PubMed
  15. J Med Screen. 2010;17(2):79-86 - PubMed
  16. J Pathol. 1999 Sep;189(1):12-9 - PubMed
  17. J Med Screen. 2010;17(2):87-90 - PubMed
  18. Eur J Cancer Prev. 2008 Oct;17(5):453-9 - PubMed
  19. Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):9-18 - PubMed
  20. Am J Clin Pathol. 2012 Apr;137(4):516-42 - PubMed
  21. Eur J Cancer. 2009 Jan;45(1):107-18 - PubMed
  22. APMIS. 2011 Oct;119(10):701-9 - PubMed
  23. Lancet. 2007 Nov 24;370(9601):1764-72 - PubMed
  24. BMC Infect Dis. 2010 Jul 20;10:214 - PubMed
  25. BJOG. 2013 Sep;120(10):1260-7; discussion 1267-8 - PubMed
  26. J Natl Cancer Inst. 2008 Apr 2;100(7):492-501 - PubMed
  27. Prev Med. 2010 Apr;50(4):159-64 - PubMed
  28. Eur J Cancer. 2013 Oct;49(15):3262-73 - PubMed
  29. Epidemiol Prev. 2015 May-Jun;39(3 Suppl 1):61-76 - PubMed
  30. Int J Cancer. 2012 Feb 15;130(4):937-47 - PubMed
  31. Epidemiol Prev. 1999;23 Suppl:1-32 - PubMed
  32. J Med Screen. 2015 Mar;22(1):38-48 - PubMed
  33. Int J Cancer. 2008 Dec 1;123(11):2664-70 - PubMed
  34. N Engl J Med. 2007 Oct 18;357(16):1589-97 - PubMed
  35. J Natl Cancer Inst. 2006 Jun 7;98(11):765-74 - PubMed
  36. Int J Epidemiol. 2010 Jun;39(3):757-65 - PubMed
  37. Obstet Gynecol. 2004 Dec;104(6):1355-61 - PubMed
  38. Ann Intern Med. 2012 Jun 19;156(12):880-91, W312 - PubMed
  39. Epidemiol Prev. 2012 Mar-Apr;36(2):108-19 - PubMed
  40. Acta Obstet Gynecol Scand. 2009;88(6):737-42 - PubMed
  41. Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72 - PubMed
  42. Epidemiol Prev. 2012 Mar-Apr;36(2):95-9 - PubMed
  43. Int J Cancer. 2006 Dec 1;119(11):2677-84 - PubMed

Publication Types